bioSeedin’s Post

Biopharma in Belgium appreciation post The OECD recently published an update on biotechnology indicators, and I’m very proud to see Belgium at the top of the list with 35.7%(!) in Biotech R&D added value Seeing Switzerland as a close second raises the question of whether there is a causal relationship between Biotech investment and quality chocolate. As a Belgian, it can be easy to overlook the role our country of 12 million people plays in Life Sciences. But the presence of leading firms Janssen Pharmaceutica, GSK, Sanofi, Pfizer, and Takeda, combined with homegrown innovators like Confo therapeutics, Agomab, and rising star Argenx, is nothing short of spectacular. All this Biotech innovation is no coincidence with world-class incubators and research institutes VIB and Imec. Of course, ONTOFORCE is a proud member of this Life Science ecosystem, supporting innovation and development within the Belgian borders and beyond! #lifesciences #biotech #pharmaceutical

Well, I had a blast at the BioAsia 2024 I must admit, there were facets of #dataanalytics within the #pharmaceutical field that were completely off my radar From predictive modeling in drug discovery to genomics data analysis for personalized medicine, how data analytics is driving innovation in #biotech #pharmainnovation are truly astounding A few other observations: 🌟 The role of AI in accelerating #drugdiscovery and #research is more significant than I ever imagined. The precision and efficiency it brings to the table are game-changers 🌟How #dataintegration from disparate sources can form cohesive, actionable insights that drastically reduce the time from research to manufacturing, to clinical adoption, to boosting operational efficiency 🌟The emerging field of digital health, leveraging big data for preventive healthcare, opens new pathways for public health improvements on a global scale Well, we at Kanerika Inc are ready to accelerate #innovationatitsbest Looking forward to hearing your thoughts.. If you met me at the event, drop a comment.. #pharmainnovation #pharmaceutical #pharma #datacentre #dataaccessibility

Discover Commercial & Business Development Opportunities with mAbxience at BIO 2024 Join mAbxience's dynamic Commercial and Business Development team at the BIO International Convention in San Diego from June 3-6, 2024. Learn how we're pioneering in the biopharmaceutical sector and how you can be part of this transformative journey. Meet Our Commercial & Business Development Leaders: - Jose Ramon Millan, Global Business Development & Business Intelligence Director, is eager to discuss strategic partnerships that can revolutionize the biopharmaceutical landscape. - Eduardo Cioppi, Global Sales Director, will share insights into our global sales strategies and how we can support your expansion goals. Why Connect with Us? - Gain insights into the latest trends and opportunities in global markets. - Discuss bespoke solutions that can enhance your business’s reach and efficacy. - Explore potential collaborations that can leverage our extensive network and expertise. 📅 Book Your Meeting: Don’t miss out on the opportunity to meet with our top executives and discover how mAbxience’s commercial strategies can benefit your business. Schedule now at: [email protected] #BIO2024 #mAbxience #BusinessDevelopment #GlobalSales #Biopharmaceuticals

📣 We're excited to announce that we'll be part of the Biotech Business Mission in Japan 2024! The biotech mission to Japan from 7-11 October 2024 offers an exclusive opportunity for European SMEs and clusters to present themselves in the Japanese biotech, pharmaceutical and healthcare sector and to explore new business opportunities. The mission includes participation in the EU-Japan Biotech & Pharma Partnering Conference in Osaka and a visit to BioJapan 2024 in Yokohama. The latter is considered the largest trade fair for biotechnology in Japan. The programme is aimed at SMEs and clusters that are active in the following sectors: ➡ Drug discovery ➡ Drug discovery support including AI-assisted drug development ➡ Regenerative medicine ➡ Digital therapeutics such as drug-device combinations, non-pharmacological therapy systems ✍ Interested parties who are active in the above-mentioned areas should apply by 6 june 2024 at the latest. Further information on the event, programme, conditions and the application form can be found here: https://lnkd.in/eiVi5TN4 #EENCanHelp #Biotech #SME

🌍 𝗥𝗲𝗳𝗹𝗲𝗰𝘁𝗶𝗻𝗴 𝗼𝗻 𝗮𝗻 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝗳𝘂𝗹 𝗟𝗲𝗰𝘁𝘂𝗿𝗲: 𝗚𝗹𝗼𝗯𝗮𝗹 𝗖𝗥𝗢 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲 𝗮𝗻𝗱 𝗖𝗲𝗻𝘁𝗿𝗮𝗹 𝗟𝗮𝗯 𝗦𝗲𝗿𝘃𝗶𝗰𝗲𝘀 🧬 Today, we had the privilege of hosting an engaging and informative lecture by Jake L. (Lee Jae-woo), Head of Business Development East Asia at George Clinical. The session provided us with invaluable insights into the latest trends and developments in the global CRO market and central lab services.   📌 𝗞𝗲𝘆 𝗧𝗼𝗽𝗶𝗰𝘀 𝗖𝗼𝘃𝗲𝗿𝗲𝗱: 𝟭. 𝘾𝙍𝙊 𝘾𝙤𝙢𝙥𝙚𝙩𝙞𝙩𝙞𝙫𝙚 𝙇𝙖𝙣𝙙𝙨𝙘𝙖𝙥𝙚: We delved into the latest trends and competitive dynamics shaping the global CRO market, providing us with a strategic edge. 𝟮. 𝙂𝙡𝙤𝙗𝙖𝙡 𝙇𝙖𝙗𝙤𝙧𝙖𝙩𝙤𝙧𝙮 𝙖𝙣𝙙 𝘽𝙞𝙤𝙖𝙣𝙖𝙡𝙮𝙩𝙞𝙘𝙖𝙡 𝙇𝙖𝙣𝙙𝙨𝙘𝙖𝙥𝙚: Lee Jae-woo shared comprehensive insights into the central lab and bioanalytical landscapes, focusing on global providers and their advancements. 𝟯. 𝙂𝙡𝙤𝙗𝙖𝙡 𝘾𝙍𝙊 𝙇𝙖𝙗𝙤𝙧𝙖𝙩𝙤𝙧𝙮 𝙋𝙖𝙧𝙩𝙣𝙚𝙧𝙨𝙝𝙞𝙥𝙨: We explored the critical aspects of selecting and collaborating with laboratory partners globally, gaining practical recommendations for enhancing our partnerships. As we expand our service globally, this lecture has enriched our knowledge and will undoubtedly enhance our approach to clinical lab services. We extend our heartfelt thanks to Lee Jae-woo for his valuable insights and to all attendees for their active participation. We're eager to leverage these learnings to drive excellence in our clinical lab services! #CentralLab #Laboratory #Lecture #LabServices #ClinicalTrials #Pharmaceutical #Biotech #DrugDevelopment #CRO #Seminar #PharmaceuticalIndustry #Innovation #Healthcare #Biotechnology

“𝐌𝐚𝐫𝐤𝐞𝐭 𝐕𝐚𝐥𝐮𝐞 𝐏𝐞𝐫 𝐄𝐦𝐩𝐥𝐨𝐲𝐞𝐞” 𝐨𝐟 𝐏𝐡𝐚𝐫𝐦𝐚 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬   I previous wrote about top pharma companies by market #value. I also wrote about the total number of their #employees. Here is a look at same companies when you normalize their market value by their number of employees, yielding a "market value per employee" metric. A company that generates greater value and wealth with fewer employees is generally considered more appealing to investors and even employees.   Today, the following companies have the highest market value per employee in #pharma and #biotech industry 1- argenx 2- Vertex Pharmaceuticals 3- Eli Lilly and Company 4- Revolution Medicines 5- Regeneron 6- Ascendis Pharma 7- Genmab 8- Ionis Pharmaceuticals, Inc. 9- AbbVie 10- Amgen 11- Novo Nordisk 12- Zoetis 13- Moderna 14- Gilead Sciences * Views and ideas are my own. The information that I provide are public and intended to be educational only and are not endorsement or financial advice. I always encourage the readers to do their own research.

[Event] Adrien C., Senior Associate at AdBio partners, will be part of the jury at the #Pharmaceutical and #Biotech EIC ePitching event. Here’s why this matters: 🌐 Deep Ecosystem Involvement: At AdBio partners, we’re not just observers; we’re active participants. Adrien’s role as a jury member underscores our commitment to fostering innovation and supporting groundbreaking startups. 👨🎓 Sector Expertise: Our team combines medical, scientific, operational, and business expertise. With a deep understanding of the entrepreneurial process, we help startups navigate the intricate landscape of life sciences. 🔬Early-Stage Pioneers: Our early-stage positioning has made us detail and data-oriented. Adrien’s keen eye ensures that we spot hidden gems and nurture them into transformative success stories. We’re not just #investors; we’re entrepreneur's partners. Adrien will be part of the jury alongside other renowned investors. Their collective insights will shape the future of healthcare and biotechnology. We’re excited to witness the impact of their expertise! Stefano Coco Marielle Mailhes Jia-Yi H. Tristan Maguet Miao He, PhD MBA Osnat Hakimi #AdBioPartners #VentureCapital #Innovation #StartupEcosystem

🎢 2023 was full of ups, downs, twists, and turns that are worth reflecting on. Looking back at biopharma funding statistics from last year can provide a glimpse into the future of drug development. Our 2023 Biopharma Funding Recap goes beneath the surface to provide you with the insights to succeed in 2024. Here's what you can expect 📚 - Cumulative funding statistics separated by region - Global funding statistics based on company size brackets - Funding statistics based on therapeutic indications - Insights on the emerging biopharma landscape - Tips for service providers to grow in 2024 Check it out! We hope you all find something in here that helps make this year the best one yet 🥇 https://lnkd.in/e4Qa38wA

Speaking highly of Pharma Meeting Brazil might seem biased, but we can’t deny it: this is an event that delivers results! Our own experience proves it. We were looking for a partner to collaborate on our editorial line, someone who deeply understood the pharmaceutical industry and could create relevant content on strategic partnerships. Finding that person seemed complicated, but the solution came from where we least expected it. During the May 2024 edition, in a conversation with our client, Dr. Fisiologia, we discovered incredible synergies! This spontaneous encounter turned into an amazing collaboration, proving that networking at Pharma Meeting Brazil goes beyond simple connections — it generates real and productive partnerships. The proof of this result is the publication "Collabs in Pharma", which offers a complete overview of alliances in the pharmaceutical industry, from research to commercialization. "Collabs in Pharma" will be available on September 6th.

What are you most excited to learn about at this year's Disruptive Technology for Clinical Trials Summit? Ahead of his session in Boston, MA, USA on 8 October, we were thrilled to speak with Alex Sverdlov, Senior Director, Statistical Scientist, Novartis to find out what he’s looking forward to most at this year’s edition. From current digital technologies and platforms trends, decentralized clinical trials, and emerging regulatory perspectives, Alex is looking forward to uniting with industry leaders from top pharma organizations to debate and discuss top strategies to Accelerate Clinical R&D, Connectivity, and Patient-Centric Outcomes. Be a part of the discussion and save 25% by registering with 4THJULY2025 today*: https://lnkd.in/eMg3JacE *Offer ends 10 July 2024. Exclusions apply. Cannot be combined with other offers. Email [email protected] for more info. #Disruptivetechnology #ClinicalTrials #StatisticalScience #DrugDevelopment #Innovation #AMGWorld #DisruptiveClinicalTrials